What are the indications for and recommended routes of progesterone administration during pregnancy?

Indications and Routes of Progesterone in Pregnancy

Progesterone is indicated in pregnancy for prevention of preterm birth in singleton gestations with either a history of prior spontaneous preterm birth (using intramuscular 17-hydroxyprogesterone caproate) or a sonographically short cervix ≤20-25 mm before 24 weeks (using vaginal progesterone). 1

Primary Indications for Progesterone in Pregnancy

1. Singleton Pregnancy with Prior Spontaneous Preterm Birth

• 17-hydroxyprogesterone caproate (17-OHPC) 250 mg intramuscularly weekly is the recommended formulation for women with a documented history of prior spontaneous preterm birth between 20 and 36 6/7 weeks of gestation. 2
• Treatment should begin at 16-20 weeks of gestation and continue until 36 weeks of gestation or delivery. 2
• Vaginal progesterone should not be used in this population, as multiple randomized controlled trials have failed to demonstrate benefit for preventing recurrent preterm birth despite heterogeneity in study designs. 2

2. Singleton Pregnancy with Sonographically Short Cervix (No Prior Preterm Birth)

For cervical length ≤20 mm before 24 weeks:

• Vaginal progesterone 200 mg daily is strongly recommended (GRADE 1A). 1
• This represents the highest level of evidence for progesterone use in pregnancy. 1

For cervical length 21-25 mm before 24 weeks:

• Vaginal progesterone should be considered based on shared decision-making with the patient (GRADE 1B). 1
• The evidence is moderately strong but not as robust as for cervical lengths ≤20 mm. 1

For cervical length 26-30 mm:

• Shared decision-making regarding vaginal progesterone versus surveillance is reasonable, considering patient preferences and additional risk factors. 1
• Serial transvaginal cervical length monitoring at approximately 1.5-week intervals is a reasonable alternative. 1

3. Twin or Multiple Gestations

• No progesterone formulation should be used for cervical shortening in twin pregnancies, regardless of cervical length (GRADE 1B). 1, 3
• Expectant management without progesterone, cerclage, or pessary is the only evidence-based approach for twins with short cervix. 3
• This recommendation applies even when cervical length is <15 mm between 15-24 weeks, which predicts preterm labor regardless of intervention. 3

Routes of Administration

Intramuscular Route

• 17-OHPC 250 mg weekly is the only intramuscular progesterone formulation with evidence for preterm birth prevention. 2
• Reserved exclusively for singleton pregnancies with prior spontaneous preterm birth. 2
• Should be continued even if cervical shortening develops during treatment, as switching to vaginal progesterone offers no additional benefit. 2

Vaginal Route

• Micronized progesterone 200 mg daily is the standard vaginal formulation. 1
• Used exclusively for singleton pregnancies with short cervix (≤25 mm) identified before 24 weeks in women without prior preterm birth. 1
• Treatment continues from diagnosis until 34 weeks of gestation. 1
• Vaginal progesterone achieves adequate endometrial transformation through first uterine pass effect, resulting in better uterine bioavailability despite lower serum levels compared to intramuscular administration. 4

Oral Route

• Oral progesterone is not recommended for preterm birth prevention, as it is rapidly metabolized in the gastrointestinal tract and has proven inferior to intramuscular and vaginal routes. 4

Critical Diagnostic Requirements

• Cervical length must be measured by transvaginal ultrasound using standardized protocols (Perinatal Quality Foundation or Fetal Medicine Foundation techniques). 1
• Transabdominal measurements are insufficient for clinical decision-making. 1
• Interventions are only indicated when measurements are obtained before 24 weeks of gestation. 1

Important Clinical Pitfalls to Avoid

Do NOT use progesterone in the following scenarios:

• 17-OHPC (including compounded formulations) for short cervix management in any pregnancy type (GRADE 1B). 1
• Any progesterone formulation in twin or multiple gestations with short cervix (GRADE 1B). 1, 3
• Cervical cerclage in singleton pregnancies without prior preterm birth when cervical length is 10-25 mm without dilation (GRADE 1B). 1
• Cervical pessary for short cervix in singleton pregnancies (GRADE 1B). 1
• Progesterone at 37 weeks or beyond for cervical thinning, as this represents normal physiological cervical ripening and requires no intervention. 5

Algorithm for Clinical Decision-Making

Step 1: Confirm singleton versus multiple gestation. 1

Step 2: Determine if patient has history of prior spontaneous preterm birth (20-36 6/7 weeks). 2

• If YES: Start 17-OHPC 250 mg IM weekly at 16-20 weeks, continue until 36 weeks. 2
• If NO: Proceed to Step 3. 1

Step 3: Obtain transvaginal cervical length measurement before 24 weeks. 1

• If ≤20 mm: Start vaginal progesterone 200 mg daily immediately (GRADE 1A). 1
• If 21-25 mm: Discuss vaginal progesterone with patient; shared decision-making (GRADE 1B). 1
• If 26-30 mm: Consider progesterone versus surveillance based on patient preference; repeat measurement in 1-2 weeks. 1
• If >30 mm: Routine prenatal care. 1

Step 4: If twin gestation with any cervical length finding, provide expectant management only—no progesterone, cerclage, or pessary (GRADE 1B). 3

Nuances in Evidence Quality

The evidence supporting vaginal progesterone for short cervix in singletons without prior preterm birth is stronger (GRADE 1A for ≤20 mm) than the evidence for 17-OHPC in women with prior preterm birth. 1 The OPPTIMUM trial demonstrated that vaginal progesterone did not reduce preterm birth rates in women with prior spontaneous preterm birth (15.9% vs 18.8% placebo), supporting the distinction between these two clinical scenarios. 2 A Saudi Arabian study suggested vaginal progesterone might be superior to 17-OHPC, but this trial enrolled a heterogeneous population with cervical insufficiency phenotypes not generalizable to U.S. practice patterns. 2